ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan
Shots:
- Under this exclusive collaboration and licensing agreement, ImmunoGen will receive an upfront payment of $34M and an additional payment upon full approval of Elahere, additional payments can be received if Takeda achieves prespecified regulatory and commercial milestones, as well as royalties
- ImmunoGen has retained exclusive production rights while Takeda will receive an exclusive license for Elahere's development and commercialization in Japan, along with regulatory responsibilities
- Elahere (mirvetuximab soravtansine-gynx) is an ADC approved for the treatment of adult patients with FRα+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment
Ref: Businesswire | Image: ImmunoGen
Related News:- ImmunoGen Entered into a Multi-Target License and Option Agreement with ImmunoBiochem to Develop Antibody-Drug Conjugates
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
